Mirion Technologies, Inc.

Mirion Technologies designs radiation detection, measurement, monitoring, and analysis products, software, and services used in nuclear, medical, defense, and scientific applications. The company helps customers safely use ionizing radiation in highly regulated environments, with a business built around technical qualification, reliability, and long-lived installed bases.

20,5 %

47,4 %

3,1 %

+7,5 %

2.83

2.34

— Mirion Technologies, Inc.
%
Nuclear & Safety72% Radiation measurement, monitoring, and safety products for nuclear power, labs, defense, and industrial users.
Medical28% Radiation safety and dosimetry solutions for cancer centers, imaging facilities, and healthcare workers.

Mirion sells to customers that operate in regulated, radiation-intensive environments where precision and compliance...

  • Nuclear power operatorsprimary

    Buy plant instrumentation, monitoring, and safety systems for operating fleets, upgrades, and decommissioning.

  • SMR developers and new nuclear entrantsprimary

    Buy highly engineered solutions and qualification-ready products for new reactor builds.

  • Medical centers and hospitalsprimary

    Buy dosimetry, imaging safety, and radiation protection tools to support patient and staff safety.

  • Government and defense customerssecondary

    Buy detection and monitoring systems for mission-critical radiation safety and security use cases.

  • Laboratories and research institutionssecondary

    Buy measurement, analysis, and monitoring products for scientific and industrial radiation applications.

Mirion is headquartered in Atlanta and operates across North America, Europe, and Asia, with facilities and sales...

  • Headquartered in Atlanta, Georgia, with global operations
  • Sales offices across North America, Europe, and Asia
  • Manufacturing and operating footprint in Europe and Asia
  • Revenue exposure to nuclear, medical, and defense markets worldwide
  • Russia-related projects create geopolitical and sanctions exposure

Mirion is expanding its installed base and product breadth through acquisitions, cross-selling, and deeper penetration...

01
Integrate Paragon and expand U.S. nuclear power coverageshort-term

Adds engineered solutions for large reactors and SMRs and deepens the U.S. market position.

02
Grow through cross-selling and installed-base upgradesmedium-term

The company can sell more products into existing nuclear and medical customers with high qualification barriers.

03
Sustain technical differentiation through R&D and qualificationslong-term

Regulated customers value reliability, compliance, and validated performance over commodity pricing.

Mirion’s results depend on regulated end markets, long qualification cycles, and customer willingness to adopt...

high

Tariffs, trade barriers, and export controls

The company sells globally and relies on cross-border supply and customer access.

Scope
International operations and sales
Materiality
high
high

Russia and Ukraine sanctions exposure

The company has Russian-related projects, receivables, guarantees, and backlog exposure.

Scope
Predominantly Nuclear & Safety
Materiality
high
medium

Acquisition integration risk

Expected benefits from Paragon depend on successful integration and retention of customer relationships.

Scope
Paragon acquisition
Materiality
high
medium

Regulatory and qualification risk

Customers require strict product specifications and approvals, which can delay revenue conversion.

Scope
Nuclear, defense, and medical end markets
Materiality
high
medium

Competitive pricing and customer concentration in regulated niches

Customers compare reliability, technical capability, and price, which can pressure margins.

Scope
Nuclear & Safety and Medical
Materiality
medium
Remaining performance obligations
Revenue timing and backlog visibility
Business combinations and purchase accounting
Goodwill, intangibles, and future impairment risk
Valuation allowances and tax differences
Reported tax expense and net income
Stock-based compensation and debt costs
Earnings, dilution, and cash flow presentation

: 28.4.2026